IDO
Indoleamine 2,3-dioxygenase (IDO) is an enzyme catalyzing the oxidative degradation of L-tryptophan in the kynurenine pathway, in which the pyrrole ring of L-tryptophan is cleaved to generate N-formyl-kynurenine. Mature human IDO enzyme is a 45 kDa monomeric protein of 403 amino acids that is encoded by the IDO gene (15 kb with 10 exons). According to X-ray crystallographic analysis, the chemical structure of human IDO enzyme consists of two distinct α-helical domains (one small and one large) and a heme prosthetic group, where the heme is coordinated to the active site by a histidine (His) imidazole as the proximal fifth ligand.
Products for IDO
- Cat.No. Product Name Information
- GC61750 (Rac)-Indoximod (Rac)-Indoximod (1-Methyl-DL-tryptophan) is an indoleamine 2,3-dioxygenase (IDO) inhibitor.
- GC60417 (S)-Indoximod (S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO). (S)-Indoximod can be used for the research of cancer.
-
GC69891
(S)-Indoximod-d3
(S)-Indoximod-d3 is the deuterated form of (S)-Indoximod. (S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO). (S)-Indoximod can be used for cancer research.
- GC19079 BMS-986205 BMS-986205 (BMS-986205) is a selective and irreversible indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 value of 1.1 nM in IDO1-HEK293 cells. BMS-986205 is well tolerated with potent pharmacodynamic activity in advanced cancers.
- GC62496 BMS-986242 BMS-986242 is an orally active, potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor. BMS-986242 can be used for the research of cancer.
- GN10414 Coptisine
- GN10577 Coptisine chloride
- GN10609 Coptisine Sulfate
- GC67714 DP00477
- GC33671 GNF-PF-3777 (8-Nitrotryptanthrin) GNF-PF-3777 (8-Nitrotryptanthrin) (8-Nitrotryptanthrin) is a potent human indoleamine 2,3-dioxygenase 2 (hIDO2) inhibitor which significantly reduces IDO2 activity with Ki of 0.97 μM.
- GC34621 IACS-8968 IACS-8968 (IDO/TDO Inhibitor) is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
- GC34622 IACS-8968 R-enantiomer IACS-8968 (R-enantiomer) is the R-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
- GC34623 IACS-8968 S-enantiomer IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
- GC14425 IDO inhibitor 1 Indoleamine-2,3-dioxygenase inhibitor
- GC15876 IDO-IN-1 indoleamine-2,3-dioxygenase (IDO) inhibitor
- GC36295 IDO-IN-11 IDO-IN-11 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 13.
- GC33963 IDO-IN-12 IDO-IN-12 is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO 2017181849 A1.
- GC33012 IDO-IN-2 IDO-IN-2 is a potent IDO inhibitor with an IC50 value of 4.52 nM in HeLa cell.
- GC33058 IDO-IN-3 An inhibitor of IDO1
- GC32899 IDO-IN-4 IDO-IN-4 (IDO-IN-4) is an indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1.
- GC34137 IDO-IN-5 (NLG-1489) IDO-IN-5 (NLG-1489) (NLG-1489) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC50 of 1-10 μM.
- GC34149 IDO-IN-6 (NLG-1486) IDO-IN-6 (NLG-1486) (NLG-1486) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, Compound 1486, has an IC50 of <1 μM.
- GC34139 IDO-IN-8 (NLG-1487) IDO-IN-8 (NLG-1487) (NLG-1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1487, has an IC50 of 1-10 μM.
- GC33191 IDO-IN-9 IDO-IN-9 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.011 μM (Kinase) and 0.0018 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 6.
- GC36294 IDO/TDO-IN-1 IDO/TDO-IN-1 (compound 25) is a highly potent and orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50s of 9.7 and 47 nM, respectively .
- GC65895 IDO1-IN-19 IDO1-IN-19 (Compound 17) is a potent inhibitor of IDO1. IDO1-IN-19 has the potential for the research of cancer diseases.
- GC65499 IDO1/2-IN-1 hydrochloride IDO1/2-IN-1 hydrochloride (compound 4t) is the first potent IDO1/IDO2 dual inhibitor with IC50s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 hydrochloride exhibits antitumor activies. Orally active.
- GC17968 INCB-024360 INCB-024360 (INCB 024360) is a potent and selective indoleamine 2,3-dioxigenase 1 (IDO1) inhibitor with an IC50 of 71.8 nM.
- GC15846 INCB024360 analogue A selective IDO1 inhibitor
- GC11066 Indoximod (NLG-8189) Indoximod (NLG-8189) (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod (NLG-8189) acts as a Trp mimetic in regulating mTOR. Indoximod (NLG-8189) is an immunometabolic adjuvant used for the research of cancer.
- GC64060 Kushenol E Kushenol E is a class of flavonoids isolated from Sophora flavescens and is a non-competitive indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 of 7.7??M and a Ki of 9.5??M, has anti-tumor activity.
- GC33287 LY-3381916 LY-3381916 is a potent, selective and brain penetrated inhibitor of IDO1 activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
- GC13519 Navoximod Navoximod (GDC-0919; NLG-?919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
-
GC11008
Necrostatin-1
A RIP1 kinase inhibitor
- GC64955 NLG802 NLG802 is a prodrug of indoximod, an orally active indoleamine 2,3-dioxygenase (IDO) inhibitor.
- GC13912 NLG919 An IDO pathway inhibitor
- GC15833 Norharmane inhibitor of indoleamine 2,3-dioxygenase
- GC39127 Palmatine Palmatine is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively.
- GC68133 Palmatine hydroxide
- GC32879 PF-06840003 (EOS200271) PF-06840003 (EOS200271) (EOS200271) is a highly selective orally bioavailable IDO-1 inhibitor with IC50s of 0.41 μM, 0.59 μM, and 1.5 μM for hIDO-1, dIDO-1, and mIDO-1, respectively.
- GC62689 PROTAC IDO1 Degrader-1 PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to Cereblon E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC50=2.84 μM).
-
GC70167
ZC0109
ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1), with IC50 values of 50 nM and 3.0 μM, respectively. ZC0109 induces the accumulation of reactive oxygen species (ROS), causing cell cycle arrest at the G1/S phase and leading to apoptosis in cancer cells.